Cat. No.: HY-B0094

Artemisinin

(Synonyms: Qinghaosu; NSC 369397)

32 Cited Publications

Customer Review

Based on 32 publication(s) in Google Scholar

Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 63968-64-9
Formula: C₁₅H₂₂O₅
Molecular Weight:282.33

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Artemisinin Chemical Structure

CAS No.: 63968-64-9

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (32)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants^[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects^[2].

IC₅₀ & Target^[2]

Plasmodium

All Parasite Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A-375	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A-431	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A-431	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human A-431 cells Antiproliferative activity against human A-431 cells	[PMID: 31945642]
A549	IC₅₀	15.2 μM Compound: 1a	Anticancer activity against human A549 cells by sulforhodamine B assay Anticancer activity against human A549 cells by sulforhodamine B assay	[PMID: 19819696]
A549	IC₅₀	>20 μM Compound: Artemisinin	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay	[PMID: 26318055]
A549	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A549	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A549	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
A549	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	>300 μM Compound: Artemisinin	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay	[PMID: 31945642]
A549	IC₅₀	>50 μM Compound: Artemisinin	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 31945642]
A549	IC₅₀	9.85 μM Compound: Artemisinin	Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
ADR5000 cell line	IC₅₀	26.9 μM Compound: artemisinin	Cytotoxicity against human CEM/ADR5000 by XTT assay Cytotoxicity against human CEM/ADR5000 by XTT assay	[PMID: 20527917]
ADR5000 cell line	IC₅₀	26.9 μM Compound: Artemisinin	Cytotoxicity against human CEM/ADR5000 by CCK-8 assay Cytotoxicity against human CEM/ADR5000 by CCK-8 assay	[PMID: 22884578]
ADR5000 cell line	IC₅₀	26.9 μM Compound: 1	Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay	[PMID: 24561670]
ADR5000 cell line	IC₅₀	26.9 μM Compound: 1	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
ADR5000 cell line	EC₅₀	26.9 μM Compound: 1	Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
BEAS-2B	IC₅₀	7.53 μM Compound: Artemisinin	Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
Breast cancer cell line	IC₅₀	>=40 μM Compound: Artemisinin	Antiproliferative activity against human Breast cancer cell line Antiproliferative activity against human Breast cancer cell line	[PMID: 31945642]
BT-549	IC₅₀	40 μM Compound: Artemisinin	Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 27010926]
CAKI-2	IC₅₀	40 μM Compound: Artemisinin	Antiproliferative activity against human CAKI-2 cells assessed as inhibition of cell growth Antiproliferative activity against human CAKI-2 cells assessed as inhibition of cell growth	[PMID: 27010926]
CCRF-CEM	IC₅₀	36.9 μM Compound: artemisinin	Cytotoxicity against human CCRF-CEM by XTT assay Cytotoxicity against human CCRF-CEM by XTT assay	[PMID: 20527917]
CCRF-CEM	IC₅₀	36.9 μM Compound: Artemisinin	Cytotoxicity against human CCRF-CEM cells by CCK-8 assay Cytotoxicity against human CCRF-CEM cells by CCK-8 assay	[PMID: 22884578]
CCRF-CEM	IC₅₀	36.9 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells by resazurin assay Cytotoxicity against human CCRF-CEM cells by resazurin assay	[PMID: 24561670]
CCRF-CEM	IC₅₀	36.9 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
CCRF-CEM	EC₅₀	36.9 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
CFU-GM	IC₅₀	385 μM Compound: 165	Cytotoxicity against human CFUGM Cytotoxicity against human CFUGM	[PMID: 17618015]
COLO 205	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
COLO 205	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human COLO 205 cells Antiproliferative activity against human COLO 205 cells	[PMID: 31945642]
Ehrlich	IC₅₀	29.8 μM Compound: 1	Cytotoxicity against mouse EAC after 3 days by MTT assay Cytotoxicity against mouse EAC after 3 days by MTT assay	[PMID: 8350087]
FM3A	EC₅₀	10 μM Compound: artemisinin	In vitro cytotoxicity in mouse mammary tumor FM3A cells In vitro cytotoxicity in mouse mammary tumor FM3A cells	[PMID: 10411480]
FM3A	EC₅₀	1 x 10^-5 M Compound: artemisinin	Compound was tested for cytotoxicity against FM3A mouse mammary cells. Compound was tested for cytotoxicity against FM3A mouse mammary cells.	[PMID: 10447961]
FM3A	EC₅₀	10 nM Compound: artemisinin	Antiproliferative activity in Mouse mammary tumor FM3A Antiproliferative activity in Mouse mammary tumor FM3A	[PMID: 10966746]
FM3A	EC₅₀	1.0 x 10^-5 M Compound: artemisinin	in vitro cytotoxicity against mouse mammary tumor in cell culture. in vitro cytotoxicity against mouse mammary tumor in cell culture.	[PMID: 11428929]
FM3A	EC₅₀	10 μM Compound: Artemisinin	Mammalian cell cytotoxicity assessed against mouse mammary tumor FM3A cells Mammalian cell cytotoxicity assessed against mouse mammary tumor FM3A cells	[PMID: 11882006]
FM3A	EC₅₀	1.0 x 10^-5 M Compound: Artemisinin	In vitro cytotoxicity against mouse mammary FM3A cells In vitro cytotoxicity against mouse mammary FM3A cells	[PMID: 12036365]
FM3A	EC₅₀	10 μM Compound: artemisinin	Effective concentration against mouse mammary FM3A cells Effective concentration against mouse mammary FM3A cells	[PMID: 12361400]
FM3A	EC₅₀	10 μM Compound: artemisinin	Compound was tested in vitro cytotoxicity against FM3A cell Compound was tested in vitro cytotoxicity against FM3A cell	[PMID: 12723958]
FM3A	EC₅₀	1.0 x 10^-5 M Compound: artemisinin	Cytotoxicity against FM3A mouse mammary cells Cytotoxicity against FM3A mouse mammary cells	[PMID: 13678413]
FM3A	IC₅₀	5.0 x 10^-9 M Compound: 1	Mean of EC50 values for FM3A cells/ mean of EC50 values for Plasmodium falciparum Mean of EC50 values for FM3A cells/ mean of EC50 values for Plasmodium falciparum	[PMID: 9057849]
HCT-116	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
HCT-116	GI₅₀	22.5 μM Compound: ART	Growth inhibition of human HCT-116 cells incubated for 24 hrs by Cell-titer Glo luminescent assay Growth inhibition of human HCT-116 cells incubated for 24 hrs by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-116	GI₅₀	4.3 μM Compound: ART	Growth inhibition of human HCT-116 cells incubated for 72 hrs by Cell-titer Glo luminescent assay Growth inhibition of human HCT-116 cells incubated for 72 hrs by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-116	GI₅₀	7.2 μM Compound: ART	Growth inhibition of human HCT-116 cells incubated for 48 hrs by Cell-titer Glo luminescent assay Growth inhibition of human HCT-116 cells incubated for 48 hrs by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-116	IC₅₀	7.2 μM Compound: ART	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-15	IC₅₀	17.2 μM Compound: 1a	Anticancer activity against human HCT15 cells by sulforhodamine B assay Anticancer activity against human HCT15 cells by sulforhodamine B assay	[PMID: 19819696]
HCT-15	IC₅₀	>300 μM Compound: Artemisinin	Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay	[PMID: 31945642]
HEK293	IC₅₀	>120 nM Compound: Artemisinin	Cytotoxicity against HEK293 cells by alamar blue assay Cytotoxicity against HEK293 cells by alamar blue assay	[PMID: 27212070]
HEK293	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human HEK293 cells Antiproliferative activity against human HEK293 cells	[PMID: 31945642]
HEK293	CC₅₀	>26 μM Compound: Artemisinin	Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay	[PMID: 34303874]
HeLa	IC₅₀	493.38 μM Compound: Artemisinin	Cytotoxicity against human HeLa cells measured at 48 hrs by MTT assay Cytotoxicity against human HeLa cells measured at 48 hrs by MTT assay	[PMID: 26099535]
HeLa	IC₅₀	493.38 μM Compound: ARS	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth	[PMID: 36538859]
Hepatocyte	EC₅₀	0.6 μM Compound: QHS, Qing-hao-su	Induction of CYP2B6 in human hepatocytes after 72 hrs relative to vehicle-treated control Induction of CYP2B6 in human hepatocytes after 72 hrs relative to vehicle-treated control	[PMID: 22679214]
Hepatocyte	EC₅₀	4 μM Compound: QHS, Qing-hao-su	Induction of CYP2A6 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control Induction of CYP2A6 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control	[PMID: 22679214]
Hepatocyte	EC₅₀	5.2 μM Compound: QHS, Qing-hao-su	Induction of CYP1A2 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control Induction of CYP1A2 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control	[PMID: 22679214]
Hepatocyte	EC₅₀	5.9 μM Compound: QHS, Qing-hao-su	Induction of CYP3A4 in human hepatocytes after 72 hrs relative to vehicle-treated control Induction of CYP3A4 in human hepatocytes after 72 hrs relative to vehicle-treated control	[PMID: 22679214]
HepG2	IC₅₀	>200 μM Compound: ART	Cytotoxicity against human HepG2 cells after 72 hrs by formazan test Cytotoxicity against human HepG2 cells after 72 hrs by formazan test	[PMID: 23685181]
HepG2	CC₅₀	>10 μM Compound: Artemisinin	Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay	[PMID: 25791675]
HepG2	IC₅₀	>10000 nM Compound: Artemisinin	Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis	[PMID: 25791675]
HepG2	IC₅₀	12 μM Compound: ART	Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells	[PMID: 26640981]
HepG2	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
HepG2	IC₅₀	>300 μM Compound: Artemisinin	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay	[PMID: 31945642]
HepG2	CC₅₀	>30 μM Compound: ART	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 33620219]
HepG2	IC₅₀	4.09 μM Compound: Artemisinin	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
HepG2	IC₅₀	97 μM Compound: ARS	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36538859]
HepG2 2.2.15	IC₅₀	55 μM Compound: 20	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion after 21 days Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion after 21 days	[PMID: 24549242]
HFF	EC₅₀	0.8 μM Compound: Artemisinin	Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	1.51 μM Compound: Artemisinin	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	1.73 μM Compound: Artemisinin	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	1.8 μM Compound: Artemisinin	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	IC₅₀	0.64 μM Compound: Artemisinin	Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days	[PMID: 20373807]
HL-60	IC₅₀	>50 μM Compound: 3	Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry	[PMID: 22985027]
HL-60	IC₅₀	40 μM Compound: Artemisinin	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27010926]
HT-29	ED₅₀	1.25 μg/mL Compound: Artemisinin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 31784199]
Huh-7	CC₅₀	>10 μM Compound: GNF-Pf-5341	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Huh-7	IC₅₀	>10 μM Compound: 1, ART	Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells after 48 hrs by luciferase assay Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells after 48 hrs by luciferase assay	[PMID: 24900781]
Huh-7	CC₅₀	>100 μg/mL Compound: Artemisinin	Cytotoxicity against human HuH7 cells after 72 hrs by MTT assay Cytotoxicity against human HuH7 cells after 72 hrs by MTT assay	[PMID: 26922227]
HUVEC	IC₅₀	>50 μM Compound: 1	Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay	[PMID: 14552753]
HUVEC	IC₅₀	1.1 μM Compound: ART	Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay	[PMID: 28549888]
K562	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 31945642]
KB	ED₅₀	>20 μg/mL Compound: artemisinin	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 11421741]
KB	IC₅₀	>20000 ng/mL Compound: artemisinin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 1294700]
KB	ED₅₀	>20 μg/mL Compound: artemisinin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 16933872]
KB	IC₅₀	>354 μM Compound: artemisinin	Cytotoxicity against human KB cells after 72 hrs by alamar blue assay Cytotoxicity against human KB cells after 72 hrs by alamar blue assay	[PMID: 19957999]
KB	IC₅₀	>20 μM Compound: Artemisinin	Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay	[PMID: 26318055]
KB	ED₅₀	1.25 μg/mL Compound: Artemisinin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 31784199]
KB	IC₅₀	>20000 ng/mL Compound: Artemisinin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8759172]
KB	IC₅₀	>20000 ng/mL Compound: artemisinin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 9134742]
KB	ED₅₀	>70900 nM Compound: artemisinin	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 9917283]
KB	IC₅₀	16 μg/mL Compound: 8	Compound was tested for in vitro cytotoxicity against KB (human epidermoid carcinoma) cell line Compound was tested for in vitro cytotoxicity against KB (human epidermoid carcinoma) cell line	10.1016/S0960-894X(97)00169-8
L02	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
L02	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
L02	IC₅₀	>100 μM Compound: ART	Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
L02	IC₅₀	0.43 μM Compound: 1b; ARS	Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 33636536]
L02	IC₅₀	8.25 μM Compound: Artemisinin	Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
L6	IC₅₀	450.5 μM Compound: art	Cytotoxicity against L6 cells Cytotoxicity against L6 cells	[PMID: 16889962]
L6	IC₅₀	450.5 μM Compound: art	Cytotoxicity against rat L6 cells after 72 hrs by microplate assay Cytotoxicity against rat L6 cells after 72 hrs by microplate assay	[PMID: 17544672]
L6	IC₅₀	450 μM Compound: ATMS	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 17948982]
L6	IC₅₀	450.5 μM Compound: artemisinin (art)	Cytotoxicity against rat L6 cells after 72 hrs by microplate alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by microplate alamar blue assay	[PMID: 18502136]
L6	IC₅₀	450 μM Compound: ATMS	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 18841956]
L6	IC₅₀	170 μM Compound: artemisinin	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 19091562]
L6	IC₅₀	450 μM Compound: ATM	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	[PMID: 19267462]
L6	IC₅₀	450.5 μM Compound: Art	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	[PMID: 19395265]
L6	IC₅₀	450.5 μM Compound: ATMS	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 19409677]
L6	IC₅₀	450 μM Compound: ATMS	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	[PMID: 19606902]
L6	IC₅₀	450.5 μM Compound: Artemisinin	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 19879671]
L6	IC₅₀	450 μM Compound: ATMS	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	[PMID: 19928900]
L6	IC₅₀	450.5 μM Compound: art	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 20709557]
L6	IC₅₀	450.5 μM Compound: art	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 22136906]
L6	IC₅₀	150 μM Compound: ATM	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	[PMID: 23795673]
L6	IC₅₀	>319 mM Compound: ATMS	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	[PMID: 23871911]
L6	IC₅₀	450.5 μM Compound: Art	Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorometry Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorometry	[PMID: 23880082]
L6	IC₅₀	>180 μM Compound: ATM	Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay	[PMID: 24268543]
L6	IC₅₀	450.5 μM Compound: At	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	[PMID: 25746816]
L6	IC₅₀	450.5 μM Compound: ART	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay	[PMID: 27344215]
L6	IC₅₀	450 μM Compound: ART	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay	[PMID: 28279559]
L6	CC₅₀	>350 μM Compound: ART	Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis	[PMID: 30615444]
L6	IC₅₀	450.5 μM Compound: ART	Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 30962114]
L6	IC₅₀	450.5 μM Compound: art	Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay	[PMID: 33148495]
L929	EC₅₀	>100 μg/mL Compound: artemisinin	Cytotoxicity against mouse L929 cells by MTT assay Cytotoxicity against mouse L929 cells by MTT assay	[PMID: 16854076]
L929	IC₅₀	>40 μg/mL Compound: Artemisinine	Cytotoxicity against mouse L929 cells after 5 days by MTT assay Cytotoxicity against mouse L929 cells after 5 days by MTT assay	[PMID: 18922036]
leukaemia cell line	IC₅₀	>=40 μM Compound: Artemisinin	Antiproliferative activity against human leukaemia cell line Antiproliferative activity against human leukaemia cell line	[PMID: 31945642]
LLC-PK1	IC₅₀	0.6 μg/mL Compound: artemisinin	Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay	[PMID: 19105653]
LS174T	EC₅₀	30 μM Compound: QHS, Qing-hao-su	Activation of human PXR expressed in human LS174T cells Activation of human PXR expressed in human LS174T cells	[PMID: 22679214]
LS174T	IC₅₀	>200 μM Compound: ART	Cytotoxicity against human LS 174T cells after 72 hrs by formazan test Cytotoxicity against human LS 174T cells after 72 hrs by formazan test	[PMID: 23685181]
MCF7	IC₅₀	1.4 x 10^-4 μM Compound: ART	Cytotoxicity against human MCF7 cells assessed as reduction in cell number after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell number after 48 hrs by MTT assay	[PMID: 28549888]
MCF7	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
MCF7	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
MCF7	ED₅₀	1.25 μg/mL Compound: Artemisinin	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 31784199]
MCF7	IC₅₀	>50 μM Compound: Artemisinin	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 31945642]
MDA-MB-231	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
MDA-MB-231	IC₅₀	>100 μM Compound: ART	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
MDA-MB-231	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	>50 μM Compound: Artemisinin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability	[PMID: 31945642]
MDA-MB-231	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 31945642]
Melanoma cell line	IC₅₀	>=40 μM Compound: Artemisinin	Antiproliferative activity against human Melanoma cell line Antiproliferative activity against human Melanoma cell line	[PMID: 31945642]
MRC5	IC₅₀	50.3 μM Compound: Artemisinin	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition and measured after 2 days by WST-8 assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition and measured after 2 days by WST-8 assay	[PMID: 35512262]
MRC5	CC₅₀	>25 μM Compound: Artemisinin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 36282784]
MRC5	IC₅₀	>25 μM Compound: Artemisinin	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth	[PMID: 38421618]
Ovarian cancer cell line	IC₅₀	>=40 μM Compound: Artemisinin	Antiproliferative activity against human Ovarian cancer cell line Antiproliferative activity against human Ovarian cancer cell line	[PMID: 31945642]
P388	ED₅₀	1.25 μg/mL Compound: Artemisinin	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 31784199]
P388	IC₅₀	28 μg/mL Compound: 8	Compound was tested for in vitro cytotoxicity against P388 (murine lymphocytic leukemia) cell line Compound was tested for in vitro cytotoxicity against P388 (murine lymphocytic leukemia) cell line	10.1016/S0960-894X(97)00169-8
PC-12	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
PC-3	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
PC-3	IC₅₀	39.03 μM Compound: Artemisinin	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 31945642]
SH-SY5Y	IC₅₀	>50 μM Compound: ART	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
SH-SY5Y	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
SK-HEP1	IC₅₀	>200 μM Compound: ART	Cytotoxicity against human SKHEP1 cells after 72 hrs by formazan test Cytotoxicity against human SKHEP1 cells after 72 hrs by formazan test	[PMID: 23685181]
SK-MEL-2	IC₅₀	12.9 μM Compound: 1a	Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 19819696]
SK-OV-3	IC₅₀	14.3 μM Compound: 1a	Anticancer activity against human SKOV3 cells by sulforhodamine B assay Anticancer activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 19819696]
SMMC-7721	IC₅₀	0.44 μM Compound: Artemisinin	Antiproliferative activity against human SMMC-7721 cells Antiproliferative activity against human SMMC-7721 cells	[PMID: 31945642]
SMMC-7721	IC₅₀	0.63 μM Compound: 1b; ARS	Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 33636536]
U-87MG ATCC	IC₅₀	>50 μM Compound: Artemisinin	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
Vero	IC₅₀	>10 μg/mL Compound: artemisinin	Cytotoxicity against african green monkey kidney Vero cells Cytotoxicity against african green monkey kidney Vero cells	[PMID: 15165136]
Vero	IC₅₀	>4.7 μg/mL Compound: artemisinin	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17134906]
Vero	IC₅₀	>4.76 μg/mL Compound: artemisinin	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 19105653]
Vero	IC₅₀	28 nM Compound: Artemisinin	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs	[PMID: 19833520]
Vero	IC₅₀	46 nM Compound: Artemisinin	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs	[PMID: 19833520]
Vero	IC₅₀	4 ng/mL Compound: Artemisinin	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	6 ng/mL Compound: Artemisinin	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	>16.86 μM Compound: Artemisinin	Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red uptake assay Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red uptake assay	[PMID: 27936446]
Vero	CC₅₀	130 μM Compound: Artemisinin	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation	[PMID: 33636304]
Vero	CC₅₀	434.6 μM Compound: ART	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37163950]
Vero	IC₅₀	31 μg/mL Compound: 8	Compound was tested for in vitro cytotoxicity against VERO (African green monkey kidney) cell line Compound was tested for in vitro cytotoxicity against VERO (African green monkey kidney) cell line	10.1016/S0960-894X(97)00169-8
XF498	IC₅₀	16.2 μM Compound: 1a	Anticancer activity against human XF498 cells by sulforhodamine B assay Anticancer activity against human XF498 cells by sulforhodamine B assay	[PMID: 19819696]

In Vitro

Artemisinin (Qinghaosu) (25 or 50 μM; 24 hours) concentration-dependently suppresses Aβ25-35 induced cytotoxicity in PC12 cells^[1].
Artemisinin (1-100 μM; 24 hours) selectively inhibits cancer cell growth in a dose-dependent manner with IC₅₀ values of 31.30 ± 0.73 μM in UMRC-2 cells and 23.97 ± 0.92 CAKI-2 cells^[2].
Artemisinin (25, 50 μM; 24 hours) suppresses the phosphorylation of AKT in UMRC-2 and CAKI-2 cells in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

PC12 cells
Concentration:

25 or 50 μM
Incubation Time:

24 hours
Result:

Protected and rescue PC12 cells against Aβ25-35-induced cell death.

Cell Viability Assay^[2]

Cell Line:

RCC cells, RCC cell lines UMRC-2 and CAKI-2, and normal renal cell HK-2
Concentration:

1, 5, 10, 50, and 100 μM
Incubation Time:

24 hours
Result:

Selectively inhibited cancer cell growth in a dose-dependent manner.

Western Blot Analysis^[2]

Cell Line:

UMRC-2 and CAKI-2 cells
Concentration:

25, 50 μM
Incubation Time:

24 hours
Result:

Decreased pAKT in a dose-dependent manner.

In Vivo

Artemisinin (gavage; 20 mg/kg/day; for two weeks) suppresses UMRC-2 xenograft tumor growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4-6 weeks old male nude mice^[2]
Dosage:

20 mg/kg
Administration:

gavage; every day for two weeks
Result:

Suppressed UMRC-2 xenograft tumor growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 63968-64-9
Appearance Solid
Molecular Weight 282.33
Formula C₁₅H₂₂O₅
Color White to off-white
SMILES

O=C1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1
Synonyms

Qinghaosu; NSC 369397
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
- Plants
- Compositae
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (32)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayWBIn Vivo Imaging

Sort by:

Journal Impact Factor

Cell Mol Immunol

Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]

2023 Jan;20(1):51-64. PMID: 36447031

Artemisinin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
Chem Eng J

2025 Oct 20;525:169775.
J Adv Res

Piezo1 activation accelerates osteoarthritis progression and the targeted therapy effect of artemisinin. [Abstract]

2024 Aug:62:105-117. PMID: 37758057

Artemisinin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:105-117. [Abstract]

ART (50 μM, 15 min) pre-incubation significantly inhibited the Yoda1-induced increase in calcium ion influx in human umbilical vein endothelial cells (HUVECs).

Artemisinin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:105-117. [Abstract]

Yoda1 greatly increased the calcium influx in OA HACs, which was dramatically reduced by addition of ART (50 μM, 15 min).

Artemisinin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:105-117. [Abstract]

CCK8 assay was used to detect the effects of different concentrations of ART (0-1000 μM) on OA HACs proliferation. The black trace represents the average response of 3-dish repeats. Error bars are shown in colors.

Artemisinin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:105-117. [Abstract]

KEGG pathway analysis of transcripts from experiments of Yoda1 and Yoda1 + ART. The three biologically independent samples in each group were combined into one.

Artemisinin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:105-117. [Abstract]

Western blot of PIEZO1, COL2A1, RUNX2 and MMP13 in OA HACs treated with Yoda1 with and without ART (50 μM) for 24 h.

Artemisinin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:105-117. [Abstract]

Representative 3D reconstruction derived from μCT scans of knee joints from Yoda1-treated mice and controls with or without ART (1 mM, 2 μL/time, intra-articular administration, once a week) treatment at 8 weeks after DMM surgery. Scale bar, 1.0 mm.
Redox Biol

USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [Abstract]

2026 May:92:104086. PMID: 41844497
Cell Mol Biol Lett

Artemisinin relieves osteoarthritis by activating mitochondrial autophagy through reducing TNFSF11 expression and inhibiting PI3K/AKT/mTOR signaling in cartilage. [Abstract]

2022 Jul 28;27(1):62. PMID: 35902802
Cancer Lett

Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization. [Abstract]

2024 Apr 10:587:216732. PMID: 38360142
Cell Death Dis

Trifluridine/tipiracil induces ferroptosis by targeting p53 via the p53-SLC7A11 axis in colorectal cancer 3D organoids. [Abstract]

2025 Apr 5;16(1):255. PMID: 40188162
Cell Death Dis

PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex. [Abstract]

2021 Mar 15;12(3):276. PMID: 33723221
Int J Biol Macromol

CircSETD3 interrupts the bidirectional positive feedback of ErbB3 and Akt by sponging miR-4667-5p to inhibit colorectal cancer progression and cetuximab resistance. [Abstract]

2025 Jun 18:145352. PMID: 40541877
Int J Biol Macromol

Porcine reproductive and respiratory syndrome virus activates lipid synthesis through a ROS-dependent AKT/PCK1/INSIG/SREBPs axis. [Abstract]

2024 Oct 19:136720. PMID: 39433189
Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Biomed Pharmacother

Inhibition of AKT enhances the anti-cancer effects of Artemisinin in clear cell renal cell carcinoma. [Abstract]

2019 Oct;118:109383. PMID: 31545251

Artemisinin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Oct;118:109383. [Abstract]

ART (Artemisinin) suppresses the phosphorylation of AKT in UMRC-2 xenograft tumor. Tumors are homogenized in RIPA buffer. The protein levels were measured by western blot analysis.
Cell Mol Life Sci

The contrasting effects of two antimalarial drugs on insulin secretion. [Abstract]

2025 Nov 25;82(1):419. PMID: 41288707
J Agric Food Chem

Chemoproteomic Profiling of Cobalamin-Independent Methionine Synthases in Plants with a Covalent Probe. [Abstract]

2020 Jul 29;68(30):8050-8056. PMID: 32618189
Inflammation

Antimalarial Drug Artemotil Promotes Induction of Type 1 Regulatory T Cells. [Abstract]

2024 Nov 28. PMID: 39607628
J Nutr Biochem

Artemisinin and its derivatives modulate glucose homeostasis and gut microbiota remodeling in a nutritional context. [Abstract]

2024 Jun 10:109687. PMID: 38866191
Eur J Pharmacol

Isolinderalactone targets TNF-α/STAT3 inflammatory pathways to attenuate psoriasis-like dermatitis. [Abstract]

2026 Mar 28:1019:178733. PMID: 41795538
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
iScience

Identification of antimalarial drugs and bradykinin as ligands of the Plasmodium membrane protein PfSR10. [Abstract]

2025 Oct 21;28(11):113807. PMID: 41280702
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
J Immunol Res

Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. [Abstract]

2022 Jun 22:2022:2253436. PMID: 35785030
Parasit Vectors

Artemisitene shows superiority over artemisinin in preventing Schistosoma japonica-induced liver disease. [Abstract]

2024 Aug 15;17(1):342. PMID: 39148111
Mol Med Rep

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. [Abstract]

2023 Jan;27(1):17. PMID: 36453238
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Brain Res

Neuronal protective effect of Artemisinin in ischemic stroke: Achieved by blocking lysine demethylase 1A-mediated demethylation of sphingosine kinase 2. [Abstract]

2024 Dec 31:149442. PMID: 39746391
Pathog Glob Health

A novel outlook in the delivery of artemisinin: production and efficacy in experimental visceral leishmaniasis. [Abstract]

2024 Feb;118(1):40-46. PMID: 37183476
Acta Histochem

Study of platelet-rich fibrin promoting endothelial cell differentiation and angiogenesis induced by transplantation of adipose-derived stem cells. [Abstract]

2023 Jun 15;125(6):152059. PMID: 37329849
Loughborough University

2025.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
Patent

US20250127769A1.
bioRxiv

Identification of α-azacyclic acetamide-based inhibitors of P. falciparum Na + pump ( Pf ATP4) with fast-killing asexual blood-stage antimalarial activity by phenotypic screening. [Abstract]

2025 May 23:2025.05.20.655166. PMID: 40475615

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (177.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5420 mL

17.7098 mL

35.4195 mL

5 mM

0.7084 mL

3.5420 mL

7.0839 mL

10 mM

0.3542 mL

1.7710 mL

3.5420 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zeng Z, et al. Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol. 2017 Apr 4;12:625-633. [Content Brief]

[2]. Lin SP, et al. Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation. Front Cell Neurosci. 2018 Apr 20;12:108. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5420 mL	17.7098 mL	35.4195 mL	88.5489 mL
	5 mM	0.7084 mL	3.5420 mL	7.0839 mL	17.7098 mL
	10 mM	0.3542 mL	1.7710 mL	3.5420 mL	8.8549 mL
	15 mM	0.2361 mL	1.1807 mL	2.3613 mL	5.9033 mL
	20 mM	0.1771 mL	0.8855 mL	1.7710 mL	4.4274 mL
	25 mM	0.1417 mL	0.7084 mL	1.4168 mL	3.5420 mL
	30 mM	0.1181 mL	0.5903 mL	1.1807 mL	2.9516 mL
	40 mM	0.0885 mL	0.4427 mL	0.8855 mL	2.2137 mL
	50 mM	0.0708 mL	0.3542 mL	0.7084 mL	1.7710 mL
	60 mM	0.0590 mL	0.2952 mL	0.5903 mL	1.4758 mL
	80 mM	0.0443 mL	0.2214 mL	0.4427 mL	1.1069 mL
	100 mM	0.0354 mL	0.1771 mL	0.3542 mL	0.8855 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Artemisinin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library